Posts Tagged ‘co:AgraQuest’
Davis, Calif.-based AgraQuest, an ag-biotech firm developing new forms of pesticide, raised $20 million in what appears to be its tenth major fundraising. The U.K.’s Loudwater Trust and existing investors, including TPG Ventures, participated in the round.
AgraQuest derives novel, organic pesticides from natural microorganisms, which the company screens in order to identify natually produced substances that have toxic effects on pests. The full process, which AgraQuest details on its Web site here, is actually quite interesting. Essentially, the company IDs a bug that seems to have evolved a decent pest-control defense, analyzes that substance to ensure that it’s not toxic to plants or other animals, and then mass-produces it using biotech methods, basically by fermenting batches of the microorganisms in big vats and then purifying the resulting pesticide.
Founded in 1995 and with a half-dozen products on the market, AgraQuest is getting a bit long in the tooth for a venture company. It tried to go public a few years ago, but withdrew its filing in 2002. It has since raised more than $60 million including the latest funding, which the company is billing as a “mezzanine” round, according to VentureWire. AgraQuest has also survived the loss of a founder, Pam Marrone, who left last year to found a competing firm, Marrone Organic Innovations.
Featured companies: AgraQuest, BridgeHealth, CardioMems, Collegium Pharmaceutical, Emergin, Entegrion, gDiapers, Precision Therapeutics, PregLem
UPDATED: Expanded items on Entegrion, Collegium, and gDiapers. Added CardioMems item. New items posted on AgraQuest (link), BridgeHealth (link) and Precision Therapeutics (link).
Entegrion draws $4.7M for bleeding control — Entegrion, a Research Triangle Park, N.C., biotech focused on products that stop bleeding, raised $4.7 million in a second funding round, VentureWire reports (subscription req’d). Investors included BD Ventures, Catalysta Partners and unnamed individuals.
Entegrion’s main product is Stasix, a formulation derived from human platelet cells that promote blood clotting. Those cells are processed and freeze-dried into a powder, which can be applied directly to wounds or reconstituted and infused throughout the body. The U.S. military has picked up the tab for much of the product’s development, courtesy of congressional earmarks arranged by the North Carolina delegation.
Specialty drug maker Collegium Pharma nets $2.5M — Collegium Pharmaceutical, a Cumberland, R.I., specialty pharma developing drugs for neurological, respiratory and skin disorders, raised $2.5 million from insiders, VentureWire reports. Westfield Life Sciences Fund and Boston Millennia Partners provided the funding.
Like most specialty pharmas, Collegium licenses cast-off or failed drugs from other companies and pushes them through clinical testing. The company, which already markets drugs for acne and wound healing, said it may seek a fourth funding round depending on its 2008 sales. Collegium hopes to request marketing approval for a new allergy early next year.
CardioMems closes $33M funding for wireless heart sensors — Atlanta’s CardioMems, a device maker focused on wireless heart sensors, raised $33 million in a fifth funding round. Investors included Arcapita Ventures, Boston Millennia Partners, Medtronic, Easton Capital Partners, Foundation Medical Partners, Arboretum Ventures, Deerfield Capital Management, Vision Capital Advisors, Aperture Venture Partners and Rockport Venture Securities.
CardioMems’ first product is a sensor that can detects the pressure within an aneurysm, a weakened section of an arterial wall that is susceptible to rupture. We previously covered the company here.
Eco-friendly gDiapers pulls in new funding — Portland, Ore.-based gDiapers, a maker of biodegradable, flushable baby diapers, raised a second funding round. The company didn’t disclose how much it raised. 2x Consumer Products Growth Partners provided the funding. (For the amusing tale of a columnist who tried these diapers — complete with a mildly panicked online comment apparently from the gDiapers CEO — see this NJ Star-Ledger piece.)
HEADLINES OF NOTE:
- AgraQuest raises $20M for biotech pesticides (release)
- Precision Thera drops IPO, goes public via reverse merger (release)
- Women’s health co. PreLem raises CHF 36M (release)
- Entegrion draws $4.7M for bleeding control (VentureWire, sub req’d)
- Specialty drug maker Collegium Pharma nets $2.5M (VW)
- Medical tourism firm BridgeHealth raises $1M+ (release)
- Eco-friendly diaper co. gDiapers raises funding (VW)
- Wireless hospital-alarm co. Emergin acquired by Philips Electronics (release)
Top Stories
- The Huffington Post confirms $25M third round
- A new, elaborate $20 billion deal for ...
- Mobile ad spending rises as iPhone effect ...
- Joost is loosed on the iPhone. Looks ...
- Breaking: Google News doesn't break tech news
Recent Guest Columnists
- Javier Rojas
The art of the bootstrap - Clifford Reid
The genomic frontier: Personalized medicine in action - Bruce Cleveland
Double down? Spin in? New questions for a new economy
Job Board
- Regional Vice President of Sales
at Marketing Technology Solutions (Jersey City, NJ) - Interactive Production Designer
at EyeWonder, Inc (233 Peachtree Street Atlanta, GA 30303) - Alliance Marketing Consultant BP
at Sun Microsystems (MENLO PARK, CA) - More Jobs » | Post a Job »
Links
Venturebeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, DigitalMedia
- Eric Eldon, Editor, DigitalMedia
- MG Siegler, Writer, DigitalMedia
- Anthony Ha, Writer, VentureBeat
- Chris Morrison, Writer, CleanTech
- For advertising, contact .
- Log in